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Abstract
Background: γ-aminobutyric acid (GABA) is an important inhibitory neurotransmitter which mainly
mediates its effects on neurons via ionotropic (GABAA) and metabotropic (GABAB) receptors. GABAB
receptors are widely expressed in the central and the peripheral nervous system. Although there is
evidence for a key function of GABAB receptors in the modulation of pain, the relative contribution of
peripherally- versus centrally-expressed GABAB receptors is unclear.
Results: In order to elucidate the functional relevance of GABAB receptors expressed in peripheral
nociceptive neurons in pain modulation we generated and analyzed conditional mouse mutants lacking
functional GABAB(1) subunit specifically in nociceptors, preserving expression in the spinal cord and brain
(SNS-GABAB(1)
-/- mice). Lack of the GABAB(1) subunit precludes the assembly of functional GABAB
receptor. We analyzed SNS-GABAB(1)
-/- mice and their control littermates in several models of acute and
neuropathic pain. Electrophysiological studies on peripheral afferents revealed higher firing frequencies in
SNS-GABAB(1)
-/- mice compared to corresponding control littermates. However no differences were seen
in basal nociceptive sensitivity between these groups. The development of neuropathic and chronic
inflammatory pain was similar across the two genotypes. The duration of nocifensive responses evoked by
intraplantar formalin injection was prolonged in the SNS-GABAB(1)
-/- animals as compared to their control
littermates. Pharmacological experiments revealed that systemic baclofen-induced inhibition of formalin-
induced nociceptive behaviors was not dependent upon GABAB(1) expression in nociceptors.
Conclusion: This study addressed contribution of GABAB receptors expressed on primary afferent
nociceptive fibers to the modulation of pain. We observed that neither the development of acute and
chronic pain nor the analgesic effects of a systematically-delivered GABAB agonist was significantly changed
upon a specific deletion of GABAB receptors from peripheral nociceptive neurons in vivo. This lets us
conclude that GABAB receptors in the peripheral nervous system play a less important role than those in
the central nervous system in the regulation of pain.
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Background
Metabotropic GABA receptors, namely GABAB receptors,
mediate the slow and prolonged physiological effects of
the inhibitory neurotransmitter, GABA. They play an
important role in the modulation of synaptic transmis-
sion. Contribution of pre- as well as post-synaptic GABAB
receptors in the modulation of long-term plasticity phe-
nomena in brain regions, such as the hippocampus and
amygdala, has been described [1-5]. GABAB receptors are
also highly concentrated in the superficial dorsal horn,
predominantly on afferent terminals of sensory neurons
located in the dorsal root ganglia (DRG) [6-9]. Amongst
these, small-diameter nociceptive neurons show a high
density of GABAB receptor expression [7,10]. However,
GABAB receptors are also expressed postsynaptically on
second order neurons and as well as at motor neuron syn-
apses [11,12]. The expression of GABAB receptor subunits
is enhanced in lumbal spinal cord and dorsal root gan-
glion following chronic nociceptive activation in models
of axotomy and chemogenic pain [13].
Multiple lines of evidence support an antinociceptive role
for GABAB  receptors in animal models of acute and
chronic pain. baclofen, a GABAB receptor agonist, exhibits
antinociceptive effects in model of peripheral nerve injury
and chronic inflammation [14]. baclofen also attenuates
pain-related behaviors evoked by the formalin injection
in rats and also reduces allodynia-like behavioral symp-
toms in disease models of chronic pain inducing monoar-
thritis [15], ischemic injury to the spinal cord [16],
carrageenan-produced inflammation [17] or trigeminal
neuralgia [18,19]. In the view of extensive literature in
animal models of acute and chronic pain, it is rather sur-
prising that the clinical administration of GABAB receptor
agonists as analgesics has been restricted to trigeminal
neuralgia and post-herpetic neuralgia [20,21]. Indeed,
GABAB receptor agonists display muscle relaxant proper-
ties and are rather widely used in the control of spasticity
[22,23] and have been implicated in dystonia [24].
Because evoked pain behaviors in animal studies mostly
rely upon a motor behavioral response, the motor deficits
caused by GABAB receptor modulation occlude an une-
quivocal interpretation of behavioral responses. Another
important caveat is that currently available GABAB ligands
suffer from lack of selectivity with respect to the locus of
action within the different components of the spinal sen-
sory-motor circuit. Thus, a complete delineation of the
sensory antinociceptive actions from the motor inhibitory
actions of GABAB receptors is not possible using the con-
ventional approach of ligand delivery in animals.
We reasoned that the application of genetic tools to
manipulate GABAB receptor expression in a site-specific
manner may enable delineating their specific role in the
modulation of nociception and chronic pain. We gener-
ated mice lacking the GABAB receptors specifically in noci-
ceptive neurons of the dorsal root ganglia. Detailed
behavioral and electrophysiological analyses in the para-
digms of basal and pathological nociception revealed that
although GABAB receptors localized in first order nocicep-
tive neurons have the capacity to modulate sensitization
phenomena, their contribution towards the modulation
of pain at the level of the whole living organism is not pro-
nounced. Furthermore, pharmacological experiments
showed that baclofen-induced antinociception is mecha-
nistically-independent of GABA receptors in the first order
nociceptive neurons.
Materials and methods
Genetically-modified mice
Homozygous mice carrying the GABAB1  flox allele
(GABAB(1) flanked by loxP sites, GABAB(1)
fl511/fl511) have
been described previously in details [25] GABAB(1)
fl511/
fl511 mice were crossed with SNS-Cre mice [26] to obtain
GABAB1-LoxPSNS-Cre+ mice (referred to as SNS-
GABAB(1)
-/- mice in this manuscript) and GABAB(1)
fl/fl mice
(control littermates). Genotyping was done on mouse
genomic tail DNA using primers: for sense strand 5'-
ATCTCTTCCTTGGCTGGGTCTTTGCTTCGCTCG-3' and
for anti-sense 5'-GGGTTATTGAATATGATCGGAATTC-
CTCGACT-3' to detect GABAB1 flox allele, and for sense
strand 5'-GAAAGCAGCCATGTCCAATTTACTGACCG-
TAC-3' and for anti-sense strand 5'-GCGCGCCTGAAGA-
TATAGAAGA-3' to detect SNS-Cre transgene expression.
Both, SNS-Cre and GABAB(1)
fl511/fl511  mice were back-
crossed individually into their background for more than
8 generations before being crossed with each other. Litter-
mates were used in all experiments to control for back-
ground effects.
Western blotting
Western blots were performed with lysates of mouse DRG,
spinal cord and brain with antibodies recognizing murine
GABAB(1) (AB1531, Chemicon) and alpha-tubulin (Sigma
Aldrich) according to standard protocols [27].
In Situ Hybridisation
For generation of riboprobes, 1.7 kb-long GABAB(1)-spe-
cific probes were generated and in situ hybridisation using
nonradioactive Dig-UTP-labelled antisense and sense
probes was performed on cryostat sections of DRG (16
μm) as described in details previously [28].
Nociceptive tests and mouse models of pain
All animal use procedures were in accordance with ethical
guidelines imposed by the local governing body
(Regierungspräsidium Karlsruhe, Germany). All behavio-
ral measurements were done in awake, unrestrained, age-
matched, female or male mice which were more than 3
months of age. Complete Freund's adjuvant (CFA, SigmaMolecular Pain 2009, 5:68 http://www.molecularpain.com/content/5/1/68
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Aldrich) was injected unilaterally in the intraplantar sur-
face of the mouse hindpaw (20 μl) as described in details
previously [29]. Analysis of latency of paw withdrawal in
response to noxious heat was done as described in details
[29] (Ugo Basile Inc.). Mechanical sensitivity was tested in
the same group of animals using von Frey hairs.
The 'spared nerve injury' (SNI) model for neuropathic
pain was performed as described in details previously
[30]. Two of the three terminal branches of the sciatic
nerve (tibial and common peroneal nerves) were ligated
and cut leaving the remaining third branch (sural nerve)
intact. Mechanical allodynia following SNI was measured
as paw withdrawal latency to dynamic von Frey stimula-
tion (Ugo Basile, maximum force 5 g, ramp 10 sec) [31].
Response to thermal stimulus (52°C) in the SNI model
was done via a hot plate latency test. The latency to paw
licking, paw withdrawal or jumping after placing the ani-
mal to the hot plate was measured. Cold allodynia follow-
ing SNI was assessed by counting the number of responses
(flinching, licking, jumping, and shaking) on a 5°C cold
plate during an observation period of 90 seconds. Addi-
tionally, cold allodynia was determined by measuring the
duration of paw licking, lifting and flinching in response
to plantar application of a drop of acetone. The nocicep-
tive behavior was observed for 90 sec starting immediately
after acetone application.
Formalin (1%, 20 μl) was injected into the plantar surface
of the hindpaw and the duration of nocifensive behaviors
(lifting, licking, or flinching) was measured in 5 min bins
for 60 min after formalin injection as described previously
[32]. baclofen (2 mg/kg of body weight; Lioresal intrathe-
cal, Novartis) or sterile PBS for control animals were
injected intraperitonially 30 min before 1% formalin
administration.
Afferent recordings in skin-nerve preparation
A total of 19 mice (10 GABAB(1)
fl/fl and 9 SNS-GABAB(1)
-/-)
were used in the electrophysiological investigations. An in
vitro skin nerve preparation was used to study the proper-
ties of mechanosensitive C- and Aδ-afferent fibers which
innervate the skin in the inflamed area. Experiments were
performed on the dissected skin of control animals and
animals sacrificed 4 hours following CFA inoculation into
the hindpaw (30 μl). Animals were killed by CO2 inhala-
tion, the saphenous nerve was dissected with the skin of
the dorsal hind-paw attached and mounted in an organ
bath "inside-up" to expose the dermis. The preparation
was perfused with an oxygen-saturated modified synthetic
interstitial fluid solution containing (in mM) 123 NaCl,
3.5 KCl, 0.7 MgSO4, 1.5 NaH2PO3, 1.7 NaH2PO4, 2.0
CaCl2, 9.5 sodium gluconate, 5.5 glucose, 7.5 sucrose, 10
Hepes at temperature of 32 ± 1°C and pH 7.4 ± 0.05. Fine
filaments were teased from the desheathed nerve placed
in separate chamber and placed on a recording electrode.
Nerve fibers were classified according to their conduction
velocities, von Frey thresholds, and firing properties. Elec-
trical stimulation of the nerve fiber was employed to cal-
culate conduction velocities of individual nerve fibers.
Fibers which conducted < 1 m/s and fibers conducting
between 1-10 m/s were considered to be unmyelinated C-
fibers and myelinated Aδ-fibers, respectively. Some of the
fibers of the velocities around 1 m/s where not included
into the analyses if further detailed classification accord-
ing to the firing properties and threshold was not possi-
ble.
Once the receptive field was identified using the glass rod
a computer-controlled linear stepping motor (Nanomo-
tor Kleindiek Nanotechnik) [33] was used to apply stand-
ardized mechanical stimuli. Each fiber was tested with
series of displacement mechanical stimuli ranging from 6
to 384 μm for both control and CFA injected animals.
Electrophysiological data were collected with Powerlab
4.0 system and analyzed off-line with the spike histogram
extension of the software.
Data analysis & statistics
All data are presented as mean ± standard error of the
mean (S.E.M.). Analysis of variance (ANOVA) for random
measures was performed followed by post-hoc Fisher's
test to determine statistically significant differences. p <
0.05 was considered significant.
Results
Conditional and specific deletion of GABAB(1) in 
nociceptors
We utilized the Cre-loxP system to generate mice condi-
tionally lacking GABAB receptors specifically in primary
nociceptors. We have previously described the generation
of BAC transgenic mice expressing the Cre-recombinase
under the influence of promoter elements of the mouse
Scn10a gene encoding the NaV1.8 sodium channel. This
line enables gene deletion specifically in c- and Aδ-nocic-
eptors in the dorsal root ganglia while preserving gene
expression in the central nervous system and other tissues
[26,34]. Mice carrying floxed GABAB1  allele [25] were
crossed with SNS-Cre+ mice to generate homozygous
mice in which the Cre-mediated excision of GABAB(1)
exon will assure the absence of GABAB1 gene product in
pre-synaptic order nociceptive neurons and their periph-
eral and central terminals. These include all of the known
C-terminal variants of GABAB(1), such as GABAB(1a), which
contributes largely to the GABAB(1) expression in nocicep-
tors, GABAB(1b), and the additional, newly described
GABAB(1e), that can mediate dominant-negative effects onMolecular Pain 2009, 5:68 http://www.molecularpain.com/content/5/1/68
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GABAB receptor heteromerization and is indeed expressed
in pain pathways [35]. Based on our understanding of
GABAB receptor heteromerization, lack of the GABAB(1)
subunit precludes the assembly of functional GABAB
receptor [28,36-38]. Previous studies have shown that the
deletion of GABAB(1) subunit is sufficient to cause the loss
of pre- and post-synaptic GABAB responses [25,39].
Western blot analysis showed that in SNS-GABAB(1)
-/- mice
expression of GABAB(1) protein in the dorsal root ganglia
(DRG) is largely reduced, whereas expression in the brain
and spinal cord remains unchanged (Fig. 1A and 1B). In
situ  mRNA hybridisation using GABAB(1)-specific ribo-
probes revealed that only a small proportion of neurons
expressing mRNA for GABAB(1) belongs to the group of
large diameter neurons. A majority of GABAB(1) expressing
DRG neurons are small-diameter neurons. SNS-GABAB(1)
-
/- mice showed a selective deletion of GABAB(1) in small
diameter neurons of the DRG whereas expression in large-
diameter neurons was preserved (Fig. 1C).
Electrophysiological analyses of peripheral nerve activity 
in SNS-GABAB(1)
-/- mice
To clarify the specific contribution of GABAB receptors on
peripheral terminals, we performed electrophysiological
recordings on peripheral polymodal C-fiber nociceptors
and Aδ nociceptors, which were identified on the basis of
stimulation and conduction properties in a hindpaw skin-
nerve preparation [33]. The skin was dissected from both
genotypes from either naive mice or 4 hours after injec-
tion of 30 μl CFA into the hindpaw.
Recordings were made from C- and Aδ-fibers because
these neurons are targeted by the SNS-Cre-mediated dele-
tion of GABAB(1). Stimulus-response functions of C-fibers
from naive SNS-GABAB(1)
-/- mice and GABAB(1)
fl/fl mice
demonstrated no significant changes between the respon-
siveness of this population to mechanical stimulation
(Fig. 2A). At 4 h following CFA-induced hind paw inflam-
mation, the excitability of mechanoreceptive C-fibers
increased significantly in GABAB(1)
fl/fl mice (Fig. 2B; p <
Conditional deletion of GABAB(1) receptor in sensory neuron specific GABAB1 knockout mice (SNS-GABAB(1)
-/-) Figure 1
Conditional deletion of GABAB(1) receptor in sensory neuron specific GABAB1 knockout mice (SNS-
GABAB(1)
-/-). (A) Western blot analysis of dorsal root ganglion (DRG), spinal cord and brain of GABAB(1)
fl/fl and SNS-
GABAB(1)
-/- using anti-GABAB(1) antibody. Equal loading of samples was controlled via analysis of tubulin expression. (B) Quanti-
tative analysis of western blot experiments. Shown are ratios of signal intensity for GABAB(1) normalized to signal intensity of 
tubulin expression (n = 3; p < 0.05; ANOVA). (C) mRNA in situ hybridization for expression of GABAB1 in DRG sections from 
GABAB(1)
fl/fl and SNS-GABAB(1)
-/-. Antisense mRNA riboprobes showed loss of signal in small-diameter DRG neurons in SNS-
GABAB(1)
-/- in comparison to their GABAB(1)
fl/fl littermates, whereas expression was retained in large-diameter cells.
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Electrophysiological analysis of excitability of peripheral nociceptive fibers in GABAB(1)
fl/fl and SNS-GABAB(1)
-/- mice in the skin  nerve preparation Figure 2
Electrophysiological analysis of excitability of peripheral nociceptive fibers in GABAB(1)
fl/fl and SNS-GABAB(1)
-/- 
mice in the skin nerve preparation. Shown are electrophysiological recordings of spike rates evoked by application of 
pressure via a nanomotor (expressed in terms of displacement) from c-mechanoceptors (C-fibers, panel A, B and C) and Aδ-
type of mechanoceptors (panel D, E and F) in the skin-nerve preparation derived from the paws of GABAB(1)
fl/fl and SNS-
GABAB(1)
-/- mice. Panel A and D represent analyses in naive GABAB(1)
fl/fl and SNS-GABAB(1)
-/-. Panels B and E represent analyses 
in GABAB(1)
fl/fl mice at 4 h following CFA-induced hindpaw inflammation. Insets show the magnification of the firing properties 
for displacements from 6 to 48 μm. Panel C and E represent analyses in SNS-GABAB(1)
-/- mice at 4 h following CFA-induced 
hindpaw inflammation. Representative traces of firing properties of C-fibers and Aδ-mechanoceptors for nanomotor displace-
ment of 48 μm are shown below the quantitative summaries. * indicates significant statistical difference (p < 0.05; ANOVA fol-
lowed by post-hoc Fisher's test). n represents the number of fiber type for each tested animal group.
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0.005, ANOVA followed by posthoc Fisher's test; typical
examples of traces are shown below the quantitative sum-
mary in Fig. 2B). Mechanoreceptive C-fibers of SNS-
GABAB(1)
-/- mice also demonstrated increased excitability
following CFA-induced inflammation; however, statisti-
cal significance was only reached at higher forces of
mechanical stimulation. Surprisingly, analysis of the basal
activity of mechanoreceptive AM-fibers (Aδ-fibers)
revealed that the basal excitability is significantly
increased in mice lacking GABAB(1) in peripheral nocicep-
tors (Fig. 2D) whereas GABAB(1)
fl/fl mice demonstrated
strong hyperexcitability to the entire range of intensities of
mechanical stimuli employed following CFA-induced
inflammation (Fig. 2E). Aδ-fibers in SNS-GABAB(1)
-/- mice
failed to demonstrate any further increases in excitability
following CFA (Fig. 2F). The magnitude of responses
shown by SNS-GABAB(1)
-/- mice to various mechanical
forces in the naive state was equivalent to those shown by
the GABAB(1)
fl/fl mice in the CFA-induced sensitized state
and no further sensitization was then seen in SNS-
GABAB(1)
-/- mice following CFA-induced inflammation.
Development of acute nociceptive hypersensitivity and its 
pharmacological modulation by baclofen
To determine how GABAB receptor affects behavioral cor-
relates of rapid sensitization in pain pathways, we per-
formed the plantar formalin test on SNS-GABAB(1)
-/-
mutant mice and their wild-type controls [32]. Intra-
plantar injection of formalin in rodents evokes nocifen-
sive behaviors such as licking, shaking, and lifting of the
injected paw in a biphasic manner. Phase I of the formalin
response (0-10 min after injection) is caused by persistent
activation and acute sensitization of nociceptors, whereas
the phase II response (10-60 min after injection) result
from continual activation of nociceptors and a sensitiza-
tion of central synapses via mechanisms which are trig-
gered by repetitive stimulation during the first phase [32].
GABAB(1) mutant mice failed to reveal changes in the total
cumulative duration of phase I and phase II responses to
formalin injection (1%, 20 μl) (Fig. 3B). However, the lat-
ter part of the phase II formalin response (so called phase
IIb, [40]) was significantly prolonged in SNS-GABAB(1)
-/-
(n = 5) when compared to GABAB(1)
fl/fl animals (n = 5)
(Fig. 3A).
Previous studies on formalin-induced nocifensive behav-
ior showed that intraperitoneal or intrathecal injection of
GABA-B receptor agonist, baclofen induces antinocicep-
tion in both phases of the formalin test [41,42]. Consist-
ent with previous studies, baclofen (2 mg/kg of body
weight), administered intraperitoneally 30 min prior to
the injection of formalin showed antinociceptive effect on
phase I and II (Fig. 3B, C; p < 0.05) behavior. However,
baclofen was equally efficient in depressing nociceptive
behavior on SNS-GABAB(1)
-/- (n = 5) and GABAB(1)
fl/fl (n =
5) mice (Fig. 3B, C; p < 0.05) suggesting that the effect of
baclofen is independent on expression of GABAB receptors
in peripheral nervous system.
Development of chronic inflammatory pain in SNS-
GABB(1)
-/- mice
Development of somatic inflammatory pain and hyperal-
gesia was assessed in GABAB(1)
fl/fl mice and SNS-GABAB(1)
-
/-mice at 12 h, 1, 2, 4, 6 and 8 days following unilateral
hindpaw inflammation induced by intraplantar injection
of complete Freud's adjuvant (CFA; 20 μl). In CFA-
injected animals paw withdrawal latency (PWL) to nox-
ious radiant heat decreased significantly for up to 4 days
(Fig. 4A). CFA-induced thermal hyperalgesia was compa-
rable in SNS-GABAB(1)
-/- (n = 6) and GABAB(1)
fl/fl (n = 6)
mice (Fig. 4B). Magnitudes of mechanical hyperalgesia
that developed after CFA injection was tested using von
Frey filaments on SNS-GABAB(1)
-/- mice, and their respec-
tive control littermates (Fig. 4C-F). Upon CFA injection,
no significant variance in the magnitudes of both allody-
nia (defined as responses to 0.16-0.4 g force) as well as
mechanical hyperalgesia (defined as responses to 0.6 - 4 g
force) was observed in SNS-GABAB(1)
-/- (n = 6) mice com-
pared to GABAB(1)
fl/fl mice (n = 6) (Fig. 4C-E). No signifi-
cant difference in the relative drop in response thresholds
that is defined as minimum force required to elicit 40%
response frequency over the basal state was observed
between genotypes (Fig. 4F). These results imply that a
loss of GABAB receptors in nociceptive DRG neurons does
not produce a major effect on nociceptive behavior and is
not involved in the modulation of chronic inflammatory
pain.
Development of neuropathic pain in SNS-GABAB(1)
-/- mice
To assess whether peripheral GABAB receptors play a role
in nociceptive hypersensitivity which develops following
a peripheral nerve lesion, we employed the spared nerve
injury model (SNI) of neuropathic pain [30]. At any of the
time points studied following injury (3, 7, 9, 16 and 23
days), no differences were found with respect to hyperal-
gesia and allodynia between SNS-GABAB(1)
-/- mice and
GABAB(1)
fl/fl mice. Following SNI, profound mechanical
allodynia was recorded by measuring paw withdrawal
latency using a dynamic aesthesiometer. Mechanical allo-
dynia developed to a similar extent in SNS-GABAB(1)
-/- and
GABAB(1)
fl/fl mice (Fig. 5A). Thermal hyperalgesia to heat
developed to a comparable extent in GABAB(1)
-/- mice and
GABAB(1)
fl/fl  mice (Fig. 5B). Similarly, cold allodynia
(responses to 5°C) developed equally in SNS-GABAB(1)
-/-
mice and GABAB(1)
fl/fl mice following SNI (Fig. 5C, D).
From these data, we infer that GABAB receptors expressed
by Aδ- and C-nociceptive peripheral neurons are not
involved in regulation of neuropathic pain.Molecular Pain 2009, 5:68 http://www.molecularpain.com/content/5/1/68
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Formalin-induced nociception and its modulation by GABAB(1) agonist, baclofen, in GABAB(1)
fl/fl and SNS-GABAB(1)
-/- mice Figure 3
Formalin-induced nociception and its modulation by GABAB(1) agonist, baclofen, in GABAB(1)
fl/fl and SNS-
GABAB(1)
-/- mice. (A) Time course of nocifensive behavior after the injection of 1% formalin into the hindpaw in SNS-
GABAB(1)
-/- mice and their control littermates. (B) Cumulative analysis of phase I (0-10 min) and phase II (10-60 min) of the for-
malin response shows no significant differences in both genotypes, SNS-GABAB(1)
-/- and GABAB(1)
fl/fl mice. Intraperitoneal injec-
tion of baclofen (2 mg/kg body weight) applied 30 minutes before intraplantar injection of formalin caused a reduction in both 
phases in GABAB(1)
fl/fl as well as SNS-GABAB(1)
-/- mice. (C) baclofen-induced modulation of the time course of the formalin 
responses foregoing by intraperitoneal injection of baclofen in GABAB(1)
fl/fl and SNS-GABAB(1)
-/-. PBS was injected in the control 
group. * indicates significant statistical difference (p < 0.05; ANOVA followed by post-hoc Fisher's test).
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Behavior analysis of GABAB(1)
fl/fl and SNS-GABAB(1)
-/- mice in the CFA model of inflammatory pain Figure 4
Behavior analysis of GABAB(1)
fl/fl and SNS-GABAB(1)
-/- mice in the CFA model of inflammatory pain. (A) Changes 
in paw withdrawal latency (in s) in response to noxious heat 12 hours and 1, 2, 4, 6 and 8 days following unilateral intraplantar 
injection of CFA. (B) Thermal hyperalgesia (changes in latency of paw withdrawal in response to noxious heat applied to the 
hindpaw plantar surface either before (basal) or at 12 h, and 1, 2, 4, 6 and 8 days) following unilateral intraplantar injection of 
CFA. Y axes represent the percent difference in paw withdrawal latency between the injected and uninjected paws calculated 
as (injected paw - uninjected paw) × 100/uninjected paw (negative values therefore indicate hyperalgesia). Comparison of 
response frequency to von Frey hairs in GABAB(1)
fl/fl (n = 6) and SNS-GABAB(1)
-/- (n = 6) mice prior to (C), 1 days (D) and 6 
days (E) following intraplantar injection of CFA. (F) Summary of threshold (defined as a force eliciting a response frequency of 
at least 40%) prior to and at 12 hours and 1, 2, 4, 6 and 8 days following intraplantar injection of CFA.
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Discussion
A large body of morphological, electrophysiological,
behavioral, and pharmacological studies have implicated
GABAB receptors in the control of pain. However, owing
to the broad expression of GABAB receptors throughout
the nervous system, spatially and temporally restricted
manipulation of GABAB receptor expression is needed to
elucidate their role at different anatomical sites along the
pain pathway. In this study, we generated mice lacking
GABAB(1) receptor specifically in the peripheral arm of the
nociceptive pathway. These mice are well-suited for eluci-
dating the relevance of GABAB receptor-mediated presyn-
aptic inhibition of neurotransmitter release from
nociceptor terminals as well as a putative role for GABAB
receptors in peripheral nociceptive terminals in physio-
logical and pathophysiological states. We analyzed mice
with respect to the excitability of nociceptors and its man-
ifestations in several models of pain, including unilateral
hindpaw inflammation, chemogenic activation of nocice-
ptors and peripheral neuropathy. Surprisingly, our
detailed analyses revealed very few phenotypic differences
between mice lacking GABAB receptors in nociceptors and
control mice. Briefly, our main findings were: 1. Chem-
ogenic pain evoked by formalin and early nociceptive
hypersensitivity were slightly prolonged in SNS-GABAB(1)
-
/- mice. 2. The magnitude and duration of chronic inflam-
matory pain and neuropathic pain was comparable
between SNS-GABAB(1)
-/- mice and control littermates. 3.
Electrophysiological analyses of nociceptor activity
revealed a higher basal excitability in Aδ-mechanoceptors
in SNS-GABAB(1)
-/- mice; however, this did not translate
into clear functional changes with respect to nociceptive
behavior.
Our findings are surprising in the view of previous studies
reporting GABAB receptor expression in primary afferent
terminals [6-9] as well as functional studies which show
that GABAB receptor activation on primary afferent termi-
nals in the spinal cord reduces neurotransmitter release
[43-45]. Although it is clear that GABAB receptors are
densely expressed in peripheral nociceptive neurons, the
literature on the regulation of GABAB receptor expression
in pathological pain states is somewhat mixed. For exam-
ple, some studies reported an increase in GABAB receptor
expression in the spinal dorsal horn and peripheral noci-
ceptors in inflammatory pain states [13]. In contrast,
Engle et al. [46] found that spinal nerve ligation does not
alter the expression or function of GABAB(1) and GABAB(2)
in the spinal cord and dorsal root ganglia of rats and also
does not lead to changes in GABAB receptor binding affin-
ity in inflammatory and neuropathic states. Furthermore,
findings in a model of diabetic neuropathy suggest
reduced function of presynaptic GABAB receptors at pri-
mary afferent terminals, but not those on GABAergic and
glycinergic interneurons, in the spinal cord [45]. Interest-
ingly, a series of experiments with novel ligands at GABAB
receptors have also suggested a functional contribution of
GABAB(1) expressed in peripheral nociceptive neurons; e.g.
α conotoxins and Rg1A peptides derived from the venom
of marine Conus snails, which are currently in develop-
ment for the treatment of neuropathic pain, have been
shown to inhibit native calcium channel currents by the
virtue of activation of GABAB receptors in first order neu-
rons [47]. Thus, considerable support implicates a role for
GABAB receptors expressed in peripheral nociceptive neu-
rons in the endogenous modulation of nociception and
pathological pain.
In this study, we deleted the primary ligand-binding sub-
unit of metabotropic GABA receptors, GABAB(1), specifi-
cally in peripheral nociceptive neurons leaving their
expression in the spinal cord and brain intact. Numerous
studies in cell lines as well as native tissues have demon-
strated that a loss of GABAB(1) leads to a complete lack of
ligand binding and a total loss of function of native
GABAB receptors [28,36-38]. Therefore, based upon our
findings, we infer that a conditional loss of GABAB recep-
tor function in peripheral nociceptive neurons in vivo does
not lead to significant changes in nociception and the
development of pathological pain.
It is interesting to note that we have found a phenotype in
firing properties of Aδ peripheral afferents, but not in C-
afferents in SNS-GABAB(1)
-/- mice compared to GABAB(1)
fl/
fl. This might result from higher expression of GABAB(1) in
Aδ- as compared to C-fibers. As noted previously GABAB
receptor mRNA has been shown to be expressed in all
DRG neurons [7]. However, studies on differential expres-
sion of the protein in different types of DRG neuron are
lacking due to antibody specificity issues. Other possible
explanation of the phenotype would be a more important
role for GABAB(1) in Aδ-fibers in comparison to C-fibers.
This hypothesis is supported by work of Sengupta et al.,
who observed a more prominent blockade of Aδ-fiber,
than C-afferent fiber, activity upon application of systemic
baclofen in pelvic nerve afferent fibers responding to iso-
baric colorectal distension [48].
It cannot be ruled out that compensatory changes, such as
an increase in inhibition via other inhibitory transmitters
and receptors, come into place to reinstate inhibition in
pathological states. However, this is unlikely given that
loss of GABAB(1) beginning at very early developmental
stages, such as in classical knockout mice, does not lead to
compensation of GABAB-mediated inhibition with
respect to pain; classical GABAB(1) knockout mice demon-
strate a prominent hyperalgesic phenotype [39]. Analyses
in classical GABAB(1) knockout mice have confirmed that
a loss of the GABAB(1) subunit is paralleled by a loss of all
biochemical and electrophysiological GABAB(1) responsesMolecular Pain 2009, 5:68 http://www.molecularpain.com/content/5/1/68
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[25,39,49], demonstrating that GABAB(1) is an essential
component of pre- and postsynaptic GABAB receptors.
Directly comparing the phenotypes of global GABAB(1)
receptor knockout mice and nociceptor-specific GABAB(1)
knockout mice therefore leads to the inference that
although GABAB  receptors in the nervous system are
important in the control of pain, these functions are likely
mediated by receptors expressed in the central nervous
system rather than those expressed in peripheral nocicep-
tive neurons. However, it deserves to be noted that classi-
cal GABAB(1) null mutants also exhibit morphological and
molecular changes in the constitution of peripheral mye-
lin and demonstrate gate abnormalities, as revealed by
very recent studies [50], thereby raising the possibility that
these alterations in the periphery may have contributed to
the sensory phenotype in GABAB(1)-deficient mice. These
abnormalities would not be expected in nociceptor-spe-
cific null mutants studied here.
Interestingly, we have found a slight phenotype in the sec-
ond phase of formalin response in SNS-GABAB(1)
-/- com-
pared to GABAB(1)
fl/fl mice. There is evidence that the
second phase of the formalin response depends not only
on central, spinal mechanisms but also on the neural
activity generated during the first phase and continuing
firing activity during the second phase [51]. Therefore, the
phenotype in phase IIb of the formalin response could be
caused by exaggerated activation of primary afferents due
to the lack of GABAB mediated inhibition in the first phase
of the formalin test.
Experimental studies with the classical GABAB receptor
agonist, baclofen, have implicated a therapeutic role for
GABAB receptors in the inhibition of nociceptive hyper-
sensitivity. However, baclofen has only found limited
clinical utility in the treatment of pain. We found that sys-
temically administered baclofen can reduce nociceptive
hypersensitivity, e.g. evoked by formalin, consistent with
previous reports [42,43,52]. However, analysis of nocice-
ptor-specific GABAB(1) receptor mutants revealed that this
anti-nociceptive activity of baclofen occurs independently
of GABAB(1) expression in peripheral nociceptive neurons.
Indeed, there is considerable evidence supporting a spinal
action of baclofen in inhibiting pain; in particular, admin-
istration of baclofen attenuates mechanical allodynia in a
rat spinal cord injury model, whereas a GABAB receptor
antagonist, phaclofen, shows opposite effects [53]. Fur-
thermore, GABAB receptors expressed in dorsal horn neu-
rons have been shown to participate in the modulation of
secondary hyperalgesia in monoarthritic rats, which is
reduced by intrathecal injection of baclofen [16]. How-
ever, some studies have also suggested a presynaptic locus
of action of baclofen. For example, electrophysiological
studies have suggested inhibition of neurotransmitter
release from presynaptic terminals via baclofen-mediated
activation of GABAB receptors [43,45]. However, the con-
sequences of baclofen-induced inhibition of presynaptic
neurotransmitter release from nociceptive afferents in the
spinal cord are somewhat tampered by the consequential
reduction of GABAergic and glycinergic synaptic transmis-
sion onto substantia gelatinosa neurons, which are typi-
cally also activated by the glutamatergic inputs coming in
via peripheral afferents [54].
Indeed, GABAB receptors are also widely distributed in a
variety of brain regions which play an important role in
the modulation of pain, e.g. the rostral agranular insular
cortex, a cortical area which is constantly activated by
painful stimuli [55]. Furthermore, it has been shown that
a local increase of GABAB concentrations in higher brain
centres results in lasting bilateral analgesia [56]. Thus, the
locus of baclofen action remains unclear.
Our analyses suggest that baclofen-induced inhibition of
anti-nociception, particularly at doses which do not cause
motor impairment, is not mediated by GABAB receptors
on presynaptic nerve terminals. A detailed analysis of
Analysis of GABAB(1)
fl/fl and SNS-GABAB(1)
-/- in the Spared  nerve injury model for neuropathic pain Figure 5
Analysis of GABAB(1)
fl/fl and SNS-GABAB(1)
-/- in the 
Spared nerve injury model for neuropathic pain. (A) 
Latency of paw withdrawal to dynamic von Frey stimulation 
in GABAB(1)
fl/fl and SNS-GABAB(1)
-/- mice before and 3,7,9,16 
and 23 days following spared nerve injury (SNI). (B) Latency 
of thermal responses via hot plate latency test (52°C) (C) 
Number of reactions to a 5°C cold stimulus (flinching, licking, 
jumping, and shaking) during an observation period of 90 sec-
onds on a cold plate. (D) Response to plantar application of 
acetone in GABAB(1)
fl/fl and SNS-GABAB(1)
-/-. All data points 
represent mean ± SEM. Statistical significance was not 
reached between mice of the two genotypes (ANOVA).
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baclofen-induced anti-nociception is considerably hin-
dered by the marked motor impairment caused by
baclofen at higher doses. We observed that intraplantar
injection of baclofen in the hind paw did not lead to anti-
nociception at low doses (data not shown); doses which
evoked anti-nociception upon intraplantar administra-
tion were accompanied by a marked impairment of motor
function and paralysis. Based upon these pieces of evi-
dence, we conclude that peripheral nociceptive neurons
are not the primary locus of baclofen action in the modu-
lation of pain.
Conclusion
In summary, this study clarifies a long-standing question
in the field of GABAergic modulation of nociception,
namely the contribution of presynaptic GABAB receptors
in primary afferent nociceptive neurons. The use of
genetic tools to specifically delete GABAB receptors in
DRG neurons, while leaving their expression in the spinal
cord and brain intact, revealed that GABAB receptors in
primary nociceptive neurons do not play a major role in
the modulation of pain. Furthermore, our results suggest
that anti-nociceptive effects evoked by GABAB receptor
agonists are not mediated by receptors in peripheral noci-
ceptive neurons but by receptors in the central nervous
system. Thus, our results suggest that it would be advanta-
geous to focus on the central nervous system when har-
nessing the GABAB receptor system for pain management.
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